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 ABSTRACT 
 Products of different origin, time of collection, and 
activities fall under the general term of colostrum and, 
therefore, great variability in composition as well as in 
the concentration of its components has been reported 
in the literature. In the present study, we describe 
the standardization of a bovine colostrum derivative 
and the characterization of its bioactive components. 
Evaluation of the most representative agents (lacto-
ferrin, transferrin, IL-2, IFN-γ, tumor necrosis factor, 
IgG, and IgA) showed that a marked decrease in active 
components occurs after the first few hours. Bovine 
colostrum was, therefore, collected up to the fifth hour 
after delivery from Holstein cows, in the presence of 
preservatives, and immediately frozen. A protocol of 
centrifugation, filtration, and lyophilization was then 
applied to pools of colostrum from at least 30 cows to 
obtain a stable, sterile, standardized product. Preserva-
tives were removed by dialysis. Evaluation of the active 
biological components of colostrum showed that the 
final product of colostrums contained significant and 
reproducible amounts of bioactive factors, including 
cytokines, immunomodulating factors, growth factors, 
and immunoglobulins. The final product appeared, 
therefore, as a sterile, pyrogen-free, standardized de-
rivative of bovine colostrum with a high concentration 
of bioactive components. 
 Key words:   colostrum ,  cytokine ,  growth factor ,  stan-
dardized product 
 INTRODUCTION 
 Colostrum and its beneficial effects have been well 
known for centuries, but only in recent times have stud-
ies analyzed the biological components responsible for 
its unique activities (Burrin et al., 1997; Koletzko et al., 
1998). Colostrum properties include effects on protec-
tion and maturation of the gastrointestinal tract (Blum 
and Hammon, 2000a; Walker, 2010). Also, it mediates 
the transfer of the mother’s defenses to the baby, which 
are not only due to immunoglobulins (Ogra and Ogra 
1978; Jochims et al., 1994; Tyler et al., 1999), but also 
to factors of the innate system (Mata and Wyatt, 1971; 
Goldman and Smith, 1973; Moro et al., 1985; Blum and 
Hammon, 2000b; Kelly and Coutts, 2000; Solomons 
2002). Moreover, colostrum or its components have 
been proposed as adjuvant agents in the treatment of 
chronic infections (Pammi and Haque, 2011; Elfstrand 
and Florén, 2010), diabetes (Kim et al., 2009), colitis 
(Lissner et al., 1996; Warny et al., 1999) and wound 
healing (Leitzel et al., 1985; Doillon et al., 2011). These 
multiple effects are clearly related to the presence of a 
large variety of active factors, including heat-resistant 
immunoglobulins, micronutrients (Feeley et al., 1983; 
Casey et al., 1985; Arnaud and Favier, 1995; Mastroeni 
et al., 2006), nucleotides (Schlimme et al., 2000), and 
oligosaccharides (Gopal and Gill, 2000), along with 
cytokines and heat-labile growth factors (Nojiri et al., 
2012; Patki et al., 2012), and complement and anti-
bacterial factors (Korhonen et al., 2000; Hanel et al., 
2003). 
 Products of different origin, time of collection, and 
activities fall under the general term of colostrum, so 
that great variability in composition of colostrum as 
well as in the concentration of the components them-
selves has been reported in the literature (Devillers et 
al., 2007; Farmer and Quesnel, 2009; Quesnel, 2011). 
This variability may depend on multiple factors, among 
them the quick fall of the concentration of active com-
ponents during the hours and days following delivery/
birth and animal breeding (Senda et al., 2011; Abd 
El-Fattah et al., 2012). Therefore, differential time of 
collection, methods of collection, and treatment may 
account for these discrepancies, as products labeled as 
colostrum have been defined as collected after 12, 24, 
or 48 h or even 4 to 5 d postparturition. 
 The aim of the present study was to create a stan-
dardized product with the highest possible content in 
defined biological components. For this purpose, we 
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thought necessary to standardize the starting material 
in terms of cow breed and timing of colostrum collec-
tion and storage after delivery. Once a common source 
for the starting product was established, we planned a 
proper assessment of this substance and standardiza-
tion of its components as mandatory to propose it as 
a biological agent. Preliminary to such standardization 
was the evaluation of the biological components present 
in colostrum at different collection times. The follow-
ing steps focused on the aim of obtaining, as a final 
product, a sterile, pyrogen-free, standardized derivative 
of bovine colostrum with the highest concentration of 
bioactive factors. We describe here the processing pro-
cedure and the characteristics of such a product.
MATERIALS AND METHODS
Colostrum Collection at Different  
Hours After Parturition
Bovine colostrum was collected from Holstein cows 
at their second or third delivery at different time points 
(from 1 up to 12 h) after parturition. At each time 
point, samples were collected from the same cow. In 
the last 55 d of gestation, cows were fed, according 
to a traditional dry period, with DM (Unifeed vacche 
asciutte, an integrated mix containing wheat and corn 
silage mix plus 25.7% row proteins and 2.4% row fats) 
produced by Consorzio Agrario di Cremona (Cremona, 
Italy). Colostrum was collected in 50-mL tubes that 
were centrifuged at 500 × g for 20 min to remove the 
cream layer. The aqueous phase of these whey samples 
was collected and stored at −20°C until ELISA analysis.
Standardized Bovine Colostrum  
Derivative Preparation
The colostrum collected from the first to the fifth 
hour after parturition (see below) was kept in 3-L con-
tainers with or without preservatives (phenoxyethanol 
2.5% and diazolidinyl urea 1%) that were immediately 
stored at −20°C. The extraction process was performed 
on stocks of 100 L for each preparation, to reduce 
individual variability, as described in the following 
steps (Figure 1). Colostrum was first diluted 1:10 in 
deionized water. Sodium chloride (Sigma-Aldrich, St. 
Louis, MO) was added to reach 0.9% concentration. 
The suspension was then centrifuged at 12,400 × 
g at 20 to 25°C and the pellet containing the lipidic 
phase was discarded. The supernatant was UF through 
a ceramic membrane with a 300-kDa cutoff at 20 to 
25°C and then dialyzed with a 5-kDa polyethersulfone 
membrane (Sigma-Aldrich) to remove the preservatives 
as assessed by HPLC. Briefly, for each preservative, a 
limit of detectability and a limit of quantification were 
determined. A Simmetry column (C18; 250 × 4.6 mm; 
5-mm film thickness; Waters Corp., Milford, MA) was 
used at room temperature, the flux being 0.8 mL/min. 
The product was then filtered under vacuum through 
regenerated cellulose 0.2-μm filters (Millipore, Billerica, 
MA) and then frozen at −20°C and lyophilized.
Bacteriological Analysis
Bacteriologic testing was performed on both colos-
trum and standardized bovine colostrum derivative 
(SBCD). Colostrum, collected in 3-L containers with 
preservatives (phenoxyethanol 2.5% and diazolidinyl 
urea 1%), was immediately stored at −20°C. The sam-
ples were thawed and immediately transferred to sterile 
plastic tubes, following a published protocol (Fecteau 
et al., 2002). In selected experiments, preservatives 
were added only after thawing. One 1:10 dilution of 
each specimen (10 g) was prepared using sterile pep-
tone physiological salt solution (pH 7). For each dilu-
tion, 10 μL was plated onto Trypticase soy agar (Difco 
Laboratories Inc., Detroit, MI) with 5% bovine blood. 
The plates were incubated at 37°C in an atmosphere 
of 5% CO2. After 24 h of incubation, the different 
colony types were counted. In the absence of bacterial 
growth, plates were incubated for another 24 to 48 h. 
Bacteriologic testing was performed following the same 
protocol on the lyophilized SBCD product (10 g in 90 
mL sterile peptone physiological salt solution, pH7). 
Bacterial counts were expressed as colony-forming units 
per gram of colostrum or SBCD. A Limulus amebocyte 
lysate test (Thermo Scientific, Rockford, IL) was per-
formed according to the manufacture’s instructions to 
evaluate the absence of endotoxins in colostrum and in 
the final product. A dichotomic outcome (+/−) was 
reported, where the positive value (+) corresponded to 
≥0.4 units per milliliter by ELISA.
Detection of Cytokines and Bioactive  
Substances by ELISA
The concentrations of lactoferrin, transferrin, IL-2, 
tumor necrosis factor (TNF), INF-γ, IgA, and IgG 
were determined using commercially available sandwich 
ELISA specific for bovine molecules. The cytokines IL-
2, TNF, and IFN-γ were measured with bovine kits 
purchased from R&D Systems (Space Import Export 
s.r.l., Milan, Italy), whereas lactoferrin, transferrin, 
IgG, and IgA kits were obtained from Bethyl Labora-
tories (Tema Ricerca s.r.l., Bologna, Italy). All proce-
dures were performed according to the instructions of 
the manufacturer. The sensitivity of the method was 
125 pg/mL for IL-2, TNF, and IFN-γ; 7.8 ng/mL for 
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lactoferrin and IgG; 3.9 ng/mL for transferrin; and 
15.62 ng/mL for IgA.
In a series of preliminary experiments, we identified 
for each substance the dilution needed to extrapolate 
the sample concentrations from the central part of 
the standard curve that was generated for each set of 
samples. For transforming growth factor (TGF)-β and 
IGF-1 evaluation, human kits were used (R&D sys-
tems, Space Import Export s.r.l.) because, as reported 
in previous literature, full cross-reactivity with the 
bovine factors is present (Hammer et al., 2004; Purup 
et al., 2007). The measured concentrations of bioactive 
substances are expressed either as amount per milliliter 
of liquid colostrum or amount per milligram of lyophi-
lized product.
Detection of Interleukins and Growth  
Factors Using the Bio-Plex System
The concentration of specific cytokines and a vast 
number of growth factors was measured using human 
kits, as full cross-reactivity with the bovine factors 
has been reported (Hammer et al., 2004; Purup et al., 
2007). The flexible Bio-Plex system (Bio-Rad Labora-
tories Inc., Hercules, CA), which is based on a capture 
sandwich immunoassay, allowed for the simultaneous 
dosage of different biomolecules to be done in a single 
microplate well. Briefly, fluorescent-dyed microspheres 
(Luminex Corp., Austin, TX) were conjugated with a 
specific primary antibody and the secondary antibody 
was biotin-labeled. A streptavidin-biotin reaction was 
used to quantify the amount of the analytes and the 
fluorescent system was used to identify the analyte. 
These assays and the antibodies underwent rigorous 
optimization to ensure the highest degree of sensitivity, 
specificity, and reproducibility. All samples were ana-
lyzed following the manufacturer’s protocol. At least 
3 independent repetitions in duplicate were made per 
experimental condition type. Analyte concentrations 
were expressed in picograms per milliliter. A standard 
curve ranging, on average, from 0.15 to 3,700 pg/mL 
(high photomultiplier tube setting) was prepared and 
then fitted by Bio-Plex Manager software.
RESULTS
Biological Factors in Colostrum  
Variation With Time From Delivery
Colostrum was collected from Holstein cows at their 
second or third delivery, as preliminary experiments 
Figure 1. Schematic representation of the different passages in the process of standardized bovine colostrum derivative (SBCD) generation.
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showed higher colostrum production in cows after 
the second delivery with respect to those at the first 
delivery (not shown). Figure 2 reports the evaluation 
of the most representative agents (lactoferrin, trans-
ferrin, cytokines, and immunoglobulins) measured in 
colostrum whey obtained from 4 cows at different hours 
after parturition. For all substances, the highest con-
centrations were measured in samples obtained in the 
first 4 h after delivery. The levels of lactoferrin and of 
the cytokine IFN-γ remained constant in all samples 
overtime (Figure 2A and D). In contrast, a clear and 
significant decrease in the concentrations of transferrin 
(panel B), IL-2 (panel C), TNF-α (panel E), and IgA 
(panel F) started to be present in colostrum samples 
obtained 10 h after parturition. Immunoglobulin G 
levels decreased after 6 h (Figure 2 G). To have the 
maximum concentrations of bioactive substances in co-
lostrum, for generation of the standardized colostrum 
product, colostrum was collected up to the fifth hour 
that followed parturition. The dry weight after lyophi-
lization of whole colostrum collected in the first 5 h 
from delivery (300 ± 22 g/L; n = 8) was higher than 
the dry weight of colostrum collected after 24 h (175 ± 
25 g/L; n = 5).
Production of SBCD
Bacteriological analysis of whole colostrum before 
the process of SBCD preparation showed that addition 
of preservatives at colostrum harvest, and not after 
thawing (see details in Materials and Methods section), 
was able to reduce bacterial growth with a high efficacy 
compared with colostrum collected in the absence of 
preservatives (Table 1). Therefore, to minimize bacte-
rial growth, colostrum was collected in the presence of 
preservatives and immediately frozen.
To obtain the SBCD, a purification process was set 
up consisting of different steps of centrifugation, mi-
crofiltration, dialysis, and lyophilization, as depicted 
in Figure 1. After removal of the lipids and casein by 
centrifugation and UF through ceramic membranes, 5 
dialysis cycles were used to remove preservatives, as 
assessed by HPLC, which remained in the final product 
in low concentration (phenoxyethanol: 0.3 g/L, dia-
zolidinyl urea: 0.5 g/L). At the end of the purification/
extraction processes (i.e., after the final filtration under 
vacuum through 0.2-μm filters) we were able to obtain 
a product pooled from around 30 cows (100 L of colos-
trums, 3 L from each cow) that was finally lyophilized.
The bacteriological analysis of the SBCD produced 
from colostrum with preservatives added at the har-
vest showed a complete lack of bacterial growth and, 
more importantly, the lack of pyrogenic product release 
within the SBCD, as assessed by negative Limulus 
amebocyte lysate assay (Table 1). Interestingly, the 
analysis of SBCD derived from colostrum collected in 
the absence of preservatives showed that the process 
of SBCD preparation reduced bacterial contamination 
with respect to the whole colostrum, possibly due to 
its filtration through 0.2-μm filters. However, SBCD 
preparation did not remove pyrogens (Table 1).
Bioactive Substances in SBCD
All bioactive factors were measured in colostrum 
and in SBCD before and after lyophilization. Table 2 
reports the amount of bioactive substances (transferrin, 
lactoferrin, cytokines, growth factors, and immunoglob-
ulins) in the whole colostrums and in the final product 
obtained after all processes (dialysis and filtration), be-
fore lyophilization. All substances were still present in 
a relevant amount in the final filtered products before 
lyophilization, although variable loss is present for most 
substances (Table 2). Similarly, all substances were 
present at measurable levels in the lyophilized filtered 
product (Table 3). In addition, by using a Bio-Plex 
platform, we also measured the concentration of several 
cytokines and a vast number of growth factors that were 
shown to be present in the lyophilized product (Figure 
3). Among growth factors, basic fibroblast growth fac-
tor, TGF-β, TNF-α, and vascular endothelial growth 
factor, and among cytokines, IL-2 and IL-17 were the 
most represented (Figure 3 A and B). The different 
SBCD preparations tested showed comparable results.
DISCUSSION
Our project focused first on the identification of con-
ditions allowing collection of samples with the highest 
content of biological components. The analysis of the 
best-known and most representative agents (lactoferrin, 
transferrin, IL-2, IFN-γ, TNF, IgG, and IgA) clearly 
show that a marked decrease in active components 
occurs after the first few hours. These data, partially 
confirming reports in the literature (Purup et al., 2007; 
Senda et al., 2011; Abd El-Fattah et al., 2012) provide a 
rational interpretation of the discrepancies in biological 
activity among commercially available nonstandardized 
products labeled as colostrum. In fact, the milking of 
the cows is usually performed twice per day; hence, the 
common harvest of commercial colostrums at 24, 48, 
and 72 h. However, as reported in the present study, 
this entails a dramatic decrease in concentration of 
some of the most relevant components, such as lactofer-
rin, cytokines, and immunoglobulins, whereas we never 
observed an increase in these factors at later times. 
Therefore, to apply the proposed extraction and purifi-
cation protocol, it is mandatory to start from the most 
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Figure 2. Evaluation of bioactive factors in the aqueous phase of colostrum collected at different time points after parturition. Data are 
means ± SEM of colostrum collected from 4 different cows, each one at all the different hours. t-test: *P < 0.05 versus colostrum collected at 1, 
2, and 4 h. TNF = tumor necrosis factor. 
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concentrated colostrum, which is that of the first 5 h. 
Moreover, if we consider that two-thirds of the product 
comprises immunoglobulins, the present protocol is the 
only one fit to ensure a considerable yield of biofactors.
The above considerations stress our planning and 
justify our decision to select the colostrum obtained be-
tween the first and the fifth hour as the source of choice 
for our product. Furthermore, we used a single type of 
cow (Holstein) and the source was colostrums after the 
second and third delivery, so as to guarantee a constant 
and abundant source of active biological components.
The second, and by no means minor, prerequisite 
of our goal was to end up with a sterile pyrogen-free 
product. This represented a particularly difficult task 
related to the harvesting conditions and was afforded 
with a 3-faceted approach. First, the bacterial growth 
was blocked by collecting colostrum directly in the pres-
ence of preservatives. In fact, the complete depletion of 
the bacteria only at the end of the collection process 
does not ensure the absence of pyrogens (which once 
introduced, cannot be removed by any means). More-
over, bacterial growth would burn out and decrease the 
content of active biological components. The following 
step was that of UF, which ensured sterility by physi-
cally removing bacteria. The final process was linked to 
the elimination of preservatives by membrane dialysis.
At the end of the process, at our disposal, we had 
a stable, sterile, standardized product. Evaluation of 
the active biological components (see above) confirmed 
that we were still able to measure a relevant amount of 
components after the sterilization process. On the other 
hand, when we compared several different lots prepared 
according to the above sequence of procedures, similar 
values were obtained, thus confirming the achievement 
of our goal of a stable, standardized product (SBCD), 
which was finally preserved as a lyophilized powder. 
The low amount of residual preservative in SBCD po-
tentially renders the product suitable for several thera-
peutic applications, such as in medical devices or for 
intradermal or subcutaneous administration. On the 
other hand, for nutritional application, the preparation 
of a SBCD product without preservatives might be 
considered in the future.
It is well known that colostrum, besides containing 
immunoglobulins, is rich in several bioactive substanc-
es. To assess the quality of the processes we used to 
achieve a final standardized product, we used as mark-
ers some colostrum key factors, such as lactoferrin and 
transferrin, which are present in high concentrations 
(Wheeler et al., 2007; Cheng et al., 2008). However, we 
also performed on the final SBCD product a search for 
a large number of bioactive factors. To our knowledge, 
this is the first study that simultaneously analyzed in 
the same bovine colostrum preparation such a large 
number of factors. This analysis was made possible 
by exploiting single classic ELISA tests along with 
an innovative soluble ELISA multiparametric method 
(Bio-Plex). As expected, the bioactive substances that 
we found in the SBCD can be roughly divided in 3 cat-
egories: antimicrobial peptides, cytokines, and growth 
factors. Although cytokines and growth factors are 
considered to be separate entities, it is important to 
appreciate that distinctions between them is sometimes 
blurred.
Lactoferrin and transferrin are involved in the 
regulation of iron metabolism and iron concentration, 
and their direct antimicrobial activity has been well 
characterized, with an activity exerted against a wide 
range of bacteria as well as viruses (Wheeler et al., 
2007). Cytokines are small soluble proteins that act in 
an autocrine/paracrine fashion by binding to specific 
cellular receptors, operating in a network and orches-
trating immune system development and function. 
Several cell types can produce cytokines: immune cells 
of innate and acquired immunity such as monocytes, 
macrophages, and T and B lymphocytes, and also 
nonimmune cells, including fibroblast and mammary 
epithelial cells (Wheeler et al., 2007).
Table 1. Bacterial count (cfu/g), generated within 1 g of colostrum or standardized bovine colostrum derivative 
(SBCD; cfu/g), along with an Limulus amebocyte lysate (LAL) assay1  
Treatment2 Test Colostrum SBCD
No preservatives Bacterial count 40 × 106 (28–67 × 106) 21.5 (10–45)
LAL + +
Preservatives added after thawing Bacterial count 33.2 × 106 (20–43 × 106) ND3
LAL + ND3
Preservatives added at the harvest Bacterial count 245 (45–350) 0
LAL − −
1Data are means (range) of 4 different preparations.
2Colostrum was collected in the absence or presence of preservatives, stored at −20°C, and thawed; alternative-
ly, preservatives were added after thawing. Standardized bovine colostrum derivative derived from colostrum 
collected in the absence or presence of preservatives was also tested. 
3ND = not done
Journal of D
airy S
cience Vol. 96 N
o. 3, 2013
B
IO
LO
G
IC
A
L C
O
M
P
O
N
E
N
TS
 IN
 A S
TA
N
D
A
R
D
IZE
D
 B
O
V
IN
E
 C
O
LO
S
TR
U
M
 D
E
R
IVATIV
E
1751
Table 2. Concentrations of bioactive substances measured in whole colostrum or in the final colostrum preparation after dialysis and filtration1 
Item
Lactoferrin  
(μg/mL)
Transferrin  
(μg/mL)
IL-2  
(pg/mL)
IFN-γ  
(pg/mL)
TNF  
(pg/mL)
IgA  
(mg/mL)
IgG  
(mg/mL)
TGF-β  
(pg/mL)
IGF-1 
(ng/mL)
Whole colostrum 34 ± 7 187 ± 25 190 ± 3 145 ± 4 245 ± 52 7 ± 0.5 41 ± 2 3,533 ± 832 170 ± 70
Filtered product 28 ± 8 41 ± 6 39 ± 4 85 ± 5 85 ± 5 1 ± 0.5 12 ± 4 1,206 ± 349 42 ± 8
1The data reported are the means ± SD obtained from 3 different preparations, each one derived from a mix of at least 30 cows to minimize individual animal variations. The 
measured concentrations are expressed as amount per milliliter of liquid product. TNF = tumor necrosis factor; TGF = transforming growth factor.
Table 3. Concentrations of bioactive substances measured in the standardized bovine colostrum derivative (SBCD)1 
Item
Lactoferrin  
(μg/mg)
Transferrin  
(μg/mg)
IL-2  
(pg/mg)
IFN-γ  
(pg/mg)
TNF2  
(pg/mg)
IgA  
(mg/mg)
IgG  
(mg/mg)
IGF-1  
(ng/mg)
Lyophilized product 2.43 ± 0.95 1 ± 0.4 2 ± 2 5 ± 1 4 ± 2 0.05 ± 0.02 0.4 ± 0.1 3 ± 1.2
1The data reported are the means ± SD obtained from 8 different preparations of SBCD, each one derived from a mix of at least 30 cows to minimize individual animal variations. 
The measured concentrations are expressed as amount per milligram of lyophilized product.
2Tumor necrosis factor.
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Cytokines act at picomolar concentrations, and evi-
dence is accumulating that they are present in human 
and bovine colostrums in quantities that can exert in 
vivo effect on the newborn recipient (Hawkes et al., 
1999). These considerations have been confirmed by 
experiments showing that bovine colostrums can modu-
late the activity of human immune cells in vitro (Biswas 
et al., 2007). Cytokines, either related to innate im-
munity, such as TNF, IL-1, monocyte chemoattractant 
protein 1, and IL-15, or regulating acquired immunity, 
such as IL-2, IL-4, IFN-γ, IL-9, and IL-17, are impor-
tant components of the SBCD. Among the identified 
cytokines, IL-17, which is the signature cytokine for T 
helper 17 (Th17) cells, is present in high concentrations 
in SBCD. Interleukin 17 has been characterized for 
its multiple properties, as it has a critical role against 
bacterial and fungal infection and possesses relevant 
proinflammatory activity (Gaffen, 2011). Recently, 
IL-17 was shown to display a regulatory role in he-
matopoiesis, being involved in the modulation of both 
hematopoietic and mesenchymal stem cells (Krstic et 
al., 2012). We also measured high levels of IL-15, which 
induces proliferation of T, B, and natural killer (NK) 
cells, stimulating the immune system maturation, and 
has unique antitumor activity (Steel et al., 2012).
An important aspect to be underlined is the fact that 
the host immune response is a fine balance between 
pro- and antiinflammatory components, and manipu-
lating these responses requires care (Leung et al., 2010; 
Valledor et al., 2010). Interestingly, both stimula-
tory proinflammatory (IL-1, TNF, IFN-γ, and IL-12; 
Valledor et al., 2010) as well as inhibitory antiinflam-
matory cytokines (IL-10, IL-1RA, and TGF-β; Leung 
et al., 2010; Yoshimura and Muto, 2011) were present 
Figure 3. Evaluation of growth factors (top) and cytokines (bottom) in the standardized bovine colostrum derivative (SBCD). Factors 
were measured using a Bio-Plex platform (Bio-Rad Laboratories Inc., Hercules, CA) and expressed as picograms per milligram of lyophilized 
product ± SEM. Eight different preparations were tested. FGF = fibroblast growth factor; TGF = transforming growth factor; NGF = nerve 
growth factor; PDGF = platelet-derived growth factor; TNF = tumor necrosis factor; VEGF = vascular endothelial growth factor; GM-CSF = 
granulocyte-macrophage colony-stimulating factor; G-CSF = granulocyte colony-stimulating factor. 
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in our final product (SBCD). Therefore, the use of this 
balanced product both in vitro and vivo should guar-
antee the avoidance of excessive stimulation/inhibition 
for fine regulation of immune responses.
Among the cytokines/growth factors measured in 
SBCD, granulocyte colony-stimulating factor and 
granulocyte-macrophage colony-stimulating factor 
are pivotal substances for the proliferation, matura-
tion, and expansion of bone marrow progenitor cells, 
and their role as stem-cell stimulating factors is now 
clear (Metcalf, 2008). Also, several growth factors 
are present in SBCD, such as peptides belonging to 
the fibroblast growth factors (Itoh and Ornitz, 2011), 
insulin-like growth factors (Wiley, 2012) and platelet-
derived growth factors (Andrae et al., 2008). As the 
physiological role of these trophic factors in colostrum 
is to regulate cell proliferation and differentiation in 
the gastrointestinal mucosa of the newborn (Playford 
et al., 2000; Purup et al., 2007), they are likely to play 
a primary role as for the regenerative and reparative 
properties of colostrum in wound healing (Leitzel et al., 
1985; Doillon et al., 2011).
CONCLUSIONS
We prepared a lyophilized colostrum derivative that 
maintained most of the bioactive factors that appear to 
be at the basis of its many nutritional, modulatory, or 
even therapeutic, applications.
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